- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
ULURU Inc. (Amex: ULU) announced today that Ronald A. Ahrens has been appointed to serve on the
Company's Board of Directors.
Mr. Ahrens has been an advisor to Merck & Company, Inc. since 1995, when
he retired as President of Merck Consumer Healthcare Group Worldwide. He had
previously served as Executive Vice President of Merck Consumer Healthcare
Group International. From 1985 to 1990 Mr. Ahrens was Consumer Group
President, North America of Bristol-Myers Squibb and previously was President
of Bristol Myers Products Division. Prior to 1985, he held senior management
and sales and marketing positions with Richardson Vicks, Bristol-Myers Squibb
and Procter and Gamble.
"I am extremely impressed with ULURU's range of innovative products and
look forward to providing insight and guidance as they commercialize their
numerous product opportunities. The company is now at a point where I believe
my experience can assist the company to enhance share holder value," said Mr.
Commenting on the appointment, Kerry P. Gray, President and Chief
Executive Officer of ULURU, stated, "We are excited to have Ron join our
Board, as he has vast experience successfully commercializing numerous
products, and has been involved with a wound care company. His extensive
industry experience and contacts will be extremely helpful as we commercialize
products both internally and with strategic partners."
About ULURU Inc.
ULURU Inc. is a specialty pharmaceutical company focused on the
development of a portfolio of wound management, plastic surgery and oral care
products to provide patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative transmucosal delivery system and
Hydrogel Nanoparticle Aggregate technology.
This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as amended,
including but not limited to statements made relating to the value of our
products in the marketplace, our ability to develop and market our
technologies and commercialization of products in the marketplace. These
statements are subject to numerous risks and uncertainties, including but not
limited to the risk factors detailed in the Company's Annual Report on Form
10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for
the quarter ended March 31, 2008 and other reports filed by us with the
Securities and Exchange Commission.
For more information, please click here
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
INVECAS to Enable ASIC Designs for Tomorrow’s Intelligent Systems on GLOBALFOUNDRIES' FDX™ Technology: INVECAS to Collaborate with GLOBALFOUNDRIES to Provide IP and End-to-End ASIC Design Services on 22FDX® and 12FDX™ Technologies September 30th, 2016
Fighting cancer with sticky nanoparticles September 27th, 2016